Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rocket Pharmaceuticals (RCKT) Interest Expenses (2016 - 2025)

Historic Interest Expenses for Rocket Pharmaceuticals (RCKT) over the last 9 years, with Q3 2025 value amounting to $473000.0.

  • Rocket Pharmaceuticals' Interest Expenses rose 42.46% to $473000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year increase of 42.49%. This contributed to the annual value of $1.9 million for FY2024, which is 58.67% up from last year.
  • As of Q3 2025, Rocket Pharmaceuticals' Interest Expenses stood at $473000.0, which was up 42.46% from $473000.0 recorded in Q2 2025.
  • Rocket Pharmaceuticals' 5-year Interest Expenses high stood at $1.7 million for Q1 2021, and its period low was $251000.0 during Q2 2021.
  • For the 5-year period, Rocket Pharmaceuticals' Interest Expenses averaged around $527210.5, with its median value being $470000.0 (2023).
  • Its Interest Expenses has fluctuated over the past 5 years, first plummeted by 8594.62% in 2021, then surged by 8525.9% in 2022.
  • Over the past 5 years, Rocket Pharmaceuticals' Interest Expenses (Quarter) stood at $463000.0 in 2021, then rose by 0.86% to $467000.0 in 2022, then grew by 0.64% to $470000.0 in 2023, then rose by 0.64% to $473000.0 in 2024, then changed by 0.0% to $473000.0 in 2025.
  • Its last three reported values are $473000.0 in Q3 2025, $473000.0 for Q2 2025, and $472000.0 during Q1 2025.